Newly Published Article Demonstrates Ultrafiltration with CHF Solutions’ Aquadex FlexFlow® System Reduces Hospital Costs b...
March 26 2019 - 8:30AM
CHF Solutions (Nasdaq: CHFS), today announced the publication of
“Ultrafiltration vs. Diuretics for Treatment of Fluid Overload in
Patients with Heart Failure: A Hospital Cost Analysis”
in the Journal of Medical Economics showing that the use of
ultrafiltration therapy with the company’s Aquadex Flex Flow System
in heart failure patients reduces hospital readmissions and
durations of stay which lowers hospital costs over a 90-day period,
compared to diuretic therapy.
“We have for some time highlighted that one of the key
advantages to ultrafiltration therapy with the Aquadex system was
the cost savings to the hospital and the healthcare system in
general,” said John Erb, chairman and CEO of CHF Solutions.
“It is gratifying to have this claim validated in a peer-reviewed
academic journal that covers economic assessments of therapeutics
and medical device interventions. We continue to believe that
ultrafiltration therapy provides a much needed clinical alternative
to diuretic therapy that also provides important economic
benefits.”
The study examined clinical data from the literature and
hospital data from the Healthcare Cost and Utilization Project to
follow a decision analytic framework outlining treatment decision,
probabilistic outcomes and associated costs for treating heart
failure patients with fluid overload (hypervolemia) with either
ultrafiltration or diuretic therapy. Results showed that
while initial healthcare costs associated with ultrafiltration
therapy were higher, fluid removal with ultrafiltration, such as
with the Aquadex Flex Flow system, reduced hospital readmissions,
leading to a cost savings of $3,975, or nearly 15 percent, compared
to diuretic therapy. The study abstract can be accessed via
https://www.ncbi.nlm.nih.gov/pubmed/30775944.
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device
company focused on commercializing the Aquadex FlexFlow system for
aquapheresis therapy. The Aquadex FlexFlow system is
indicated for temporary (up to eight hours) ultrafiltration
treatment of patients with fluid overload who have failed diuretic
therapy and extended (longer than 8 hours) ultrafiltration
treatment of patients with fluid overload who have failed diuretic
therapy and require hospitalization. All treatments must be
administered by a healthcare provider, under physician
prescription, both of whom having received training in
extracorporeal therapies. The company's mission is to
predict, measure, and control patient fluid balance through
science, collaboration, and innovative medical technology.
CHF Solutions is a Delaware corporation headquartered
in Minneapolis, Minnesota with wholly owned subsidiaries
in Australia and Ireland. The company has been
listed on the Nasdaq Capital Market since February 2012.
Forward-Looking Statements
Certain statements in this release may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, the benefits of ultrafiltration therapy as compared to
diuretic therapy. Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause
actual future events to differ materially from the forward-looking
statements in this release, including, without limitation, those
risk associated with our ability to execute on our commercial
strategy, the possibility that we may be unable to raise sufficient
funds necessary for our anticipated operations, benefits of our
products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
our ability to integrate acquired businesses, our expectations
regarding anticipated synergies with and benefits from acquired
businesses, and other risks and uncertainties described in our
filings with the SEC. Forward-looking statements speak
only as of the date when made. CHF Solutions does not
assume any obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACTS:
INVESTORS: Claudia Napal Drayton Chief
Financial Officer CHF Solutions, Inc. 952-345-4205
ir@chf-solutions.com
-or- Bret Shapiro Managing Partner CORE IR 516-222-2560
brets@coreir.com www.coreir.com
MEDIA Jules Abraham JQA Partners, Inc.
917-885-7378 jabraham@jqapartners.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024